When Oncology NDAs Fail, Clinical Benefit Is Often In Question
This article was originally published in The Pink Sheet Daily
Executive Summary
Pre-submission meetings can address questions of clinically meaningful endpoints and appropriate subgroups, avoiding negative regulatory outcomes, FDA analysis suggests.
You may also be interested in...
A Cautious Guide To The Interpretation Of Clinical Trials From NEJM
Determining the success or failure of a randomized trial requires looking beyond the p-value for the primary endpoint, review articles in The New England Journal of Medicine urge.
REMS, ‘Breakthrough’ Meetings Get ‘Type B’ Tag In Revised FDA Guidance
In other modifications, FDA tells sponsors seeking Type A meetings – the most urgent category – that data packages must accompany the request.
PTC’s Upstaza Takes Gene Therapy Straight To Brain (And US FDA); Translarna To Return Mid-Year
In a year full of regulatory milestones for the firm, PTC Therapeutics hopes to set some approval precedents – and basically hopes its candidates have an easier time of it than they have had before.